IARC: ~760,000 New Stomach Cancer Cases Tied to H. pylori in 2024

IARC researchers estimate that approximately 760,000 new gastric cancer cases in 2024 were attributable to Helicobacter pylori infection.

Almost 1 million people developed gastric cancer worldwide in 2024, while nearly 650,000 died from the disease, according to global estimates released by researchers at the International Agency for Research on Cancer (IARC) on November 3, 2026.

The figures position gastric cancer, also known as stomach cancer, as both the fifth most common cancer type and the fifth leading cause of cancer death worldwide.

Among those global figures, approximately 760,000 new gastric cancer cases in 2024 were attributable to Helicobacter pylori infection. This bacterial driver accounts for about three quarters of the total global burden of gastric cancer, making H. pylori responsible for more cancer cases than any other infectious agent, including human papillomavirus, hepatitis B virus, and hepatitis C virus.

The latest data show that almost two thirds of new cases and deaths from gastric cancer occur among men. Geographically, the burden is distributed unequally, with Asia carrying the greatest impact. China alone accounts for more than one third of all global cases and deaths.

H. pylori is a spiral-shaped bacterium that infects the stomach lining, often acquired during childhood and capable of persisting for decades without symptoms. While it can cause chronic gastritis and peptic ulcers, the IARC recognizes H. pylori as a Group 1 carcinogen.

As an intergovernmental agency forming part of the World Health Organization of the United Nations, the International Agency for Research on Cancer plays a central role in global health policy. Its mission is to conduct and coordinate research into the causes of cancer while collecting and publishing surveillance data regarding the occurrence of the disease worldwide.

Through its specialized IARC monographs programme, the organization identifies carcinogenic hazards and evaluates environmental causes of cancer in humans. This evaluative unit utilizes expert groups to classify agents and exposures based on scientific evidence, providing the authoritative scientific foundation for international cancer prevention strategies.

IARC scientists lead and participate in projects exploring the feasibility and implementation of screening programs for H. pylori and gastric cancer to reduce future cases and deaths.

Although the infection can be treated with antibiotics, researchers note that large-scale treatment carries the risk of contributing to antibiotic resistance, a factor that must be weighed against potential benefits. Additional IARC research focuses on understanding the causes of the disease and establishing global guidelines for prevention.

Photo of author

Health Desk

Health Desk at Archyde.

Shenzhen Highlights AI Humanoid Robots in Manufacturing